^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Invasive breast cancer: HER2 negative....Useful in certain circumstances:...Carboplatin + paclitaxel or albumin-bound paclitaxel
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

    Excerpt:
    ...- 3.Immunohistochemical detection of ER+, PR+, HER-2 negative (if HER2 expression is 2+ patients need to be confirmed by in situ hybridization to detect...
    Trial ID:
    NCT03799692
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

    Excerpt:
    ...HER2 negative disease 4....
    Trial ID:
    NeoTRIPaPDL1
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

    Excerpt:
    ...- Patients with metastatic triple negative breast cancer (mTNBC), defined by pathological criteria: oestrogen receptor expression <10%, progesterone receptor expression <10%, HER2 negative, on the primary tumour or a metastatic biopsy...
    Trial ID:
    MIMIR-mTNBC